Erythrodermie mit Brentuximab‐Vedotin (Hautnebenwirkungen bei Mycosis fungoides)

2021 ◽  
Vol 19 (1) ◽  
pp. 99-102
Author(s):  
Alessandro Pileri ◽  
Alba Guglielmo ◽  
Annalisa Patrizi ◽  
Beatrice Casadei ◽  
Clara Bertuzzi ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Brentuximab Vedotin

Guttate psoriasis in a patient with Mycosis Fungoides in treatment with Brentuximab vedotin: an unreported association

2022 ◽  
Author(s):  
Gabriele Roccuzzo ◽  
Francesco Cavallo ◽  
Gianluca Avallone ◽  
Paolo Fava ◽  
Luca Conti ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Brentuximab Vedotin ◽  
Guttate Psoriasis

Poikilodermatous mycosis fungoides with CD30‐positive large cell transformation successfully treated by brentuximab vedotin

2019 ◽  
Vol 33 (1) ◽  
Author(s):  
Svetlana Popadic ◽  
Branislav Lekic ◽  
Srdjan Tanasilovic ◽  
Martina Bosic ◽  
Milos Nikolic
Keyword(s):  
Mycosis Fungoides ◽  
Cell Transformation ◽  
Large Cell ◽  
Brentuximab Vedotin ◽  
Large Cell Transformation

New therapies and old side‐effects in mycosis fungoides treatment: brentuximab vedotin‐induced alopecia

2019 ◽  
Vol 180 (6) ◽  
pp. 1535-1536 ◽  
Author(s):  
A. Pileri ◽  
M. Starace ◽  
A. Alessandrini ◽  
B. Casadei ◽  
P.L. Zinzani ◽  
...  
Keyword(s):  
Side Effects ◽  
Mycosis Fungoides ◽  
Brentuximab Vedotin ◽  
New Therapies

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 804-804 ◽  
Author(s):  
Youn H. Kim ◽  
Mahkam Tavallaee ◽  
Sima Rozati ◽  
Uma Sundram ◽  
Katrin Salva ◽  
...  
Keyword(s):  
Image Analysis ◽  
Clinical Response ◽  
Mycosis Fungoides ◽  
Phase Ii ◽  
Research Funding ◽  
Brentuximab Vedotin ◽  
Multispectral Image ◽  
Clinical Activity ◽  
Infiltrating Cells ◽  
Significant Clinical Activity

Abstract Background: Brentuximab vedotin (BV) is an anti-CD30 chimeric antibody conjugated by a protease-cleavable linker to the microtubule-disrupting agent, MMAE. While CD30 expression of malignant cells in HL and ALCL is uniform, in mycosis fungoides/Sezary syndrome (MF/SS), the CD30 expression is more variable. We reported previously (ASH 2012) that BV has clinical activity in MF/SS across all CD30 expression levels. In this final report, we update the clinical data and present new biomarker and correlative tissue analyses. Methods: Patients (pts) with MF/SS stages IB-IV, ECOG 0-2, with at least 1 prior systemic therapy were enrolled in this investigator-initiated, phase II, single-arm study. CD30 expression levels in the skin (% of total mononuclear cell infiltrate) were evaluated by routine immunohistochemistry (IHC) using the BerH2 antibody. At least 2 skin biopsies were obtained per pt and the max CD30 level was used for CD30 designation. All pts (CD30, 0-100%) were treated with up to 8 cycles of BV (1.8 mg/kg) administered every 3 weeks; optional extension of up to 8 additional cycles was allowed in responders with ongoing clinical improvement. Primary endpoint was overall response rate (ORR) by consensus global response criteria. CD30 expression and clinical response data were confirmed by independent review. Tumor microenvironment was assessed utilizing IHC for CD8, CD20, CD163, FoxP3, and PD-1. Multispectral image analysis was utilized to evaluate CD30 antigen co-expression. Results: 32 pts were enrolled and all received at least one dose of BV (Table); all included in safety data, 2 excluded in efficacy analyses (no response assessment). Median age was 62 (20-87). 28/32 (88%) had advanced disease, majority with adverse prognostic features (90% large cell transformation or folliculotropism). ORR was 70% (21/30) with responses in all clinical stages. Median best mSWAT reduction (response measure in the skin) was 73% (range, 100% to -54%) with 1 CR, 7 near CR in skin (>90% reduction) (Fig 1). Median time to response was 6.6 weeks (range 3.0-27.0). Kaplan-Meyer estimate shows 79% of responses ongoing and 54% progression-free at 12 months. Related AEs observed were mostly grade 1-2 and limited to AEs previously reported with BV. By IHC, median max CD30 expression level of all pts was 13% (range 0-100%; 6 had <5%), where the median was higher in responders (CR/PR), 15%, vs. non-responders (SD/PD), 3.0%, p=0.037 (Fig 1). The correlation with CD30 level was greatest in IIB/skin tumor subset (p=0.0072). Those with CD30 level <5% had a lower likelihood of clinical response (17% vs 83%; p=0.0046). Multispectral image analysis demonstrated quantifiable CD30 staining in 19/20 (95%) samples that were interpreted as negligible CD30 by routine IHC. Of other tissue biomarkers evaluated, CD163+ cells (macrophages) were most abundant with a median of 40% (range 5-80%) of total infiltrate. To distinguish expression of CD30 by neoplastic CD4+ vs. tumor-infiltrating cells, double staining for CD30 and CD8 or CD163 was assessed. We observed significant co-expression of CD30 by CD163+ macrophages (median 9.7% of total cells assessed, range 1.0-40.9%) or CD8+ cytotoxic T cells (median 1.7%, range 0.2-14.8%) (Fig 2). Those with lower CD163 relative to CD30 stain (CD163/CD30 ratio) by routine IHC were associated with clinical response (p=0.033). This may simply reflect the influence of CD30 level; however, in light of the co-localization data, it might also suggest that infiltrating macrophages that co-express CD30 may play a role as a microenvironment factor in clinical response to BV. Conclusions: Our final analysis confirms significant clinical activity of BV in MF/SS with expected AE profile. Although clinical response was observed at all levels of CD30 expression, the likelihood of response was lower in those with negligible or very low (<5%) level. We utilized multispectral imaging to enhance detection of CD30 and also show co-expression of CD30 by tumor-infiltrating cells. These findings suggest that further studies of biomarkers are warranted and may help optimize management strategies with BV. Table Characteristic All Pts n=32 Evaluable n=30 ORR n (%) n (%) CR PR SD PD Clinical Stage All pts IB IIB IV/SS 32 (100) 4 (13) 18 (56) 10 (31) 1 0 0 1 20 3 14 3 4 1 2 1 5 0 2 3 21/30 (70) 3/4 (75) 14/18 (78) 4/8 (50) Transformed or folliculotropic MF 29 (91) 1 19 3 5 20/28 (71) # prior systemic tx <3 >=3 15 (47) 17(53) 0 1 8 12 2 2 4 1 8/14 (57) 13/16 (81) Figure 1 Figure 1. Figure 2 Figure 2. Disclosures Kim: Actelion: Consultancy; Celgene: Advisory, Advisory Other; Eisai: Research Funding, SAC/Advisory, SAC/Advisory Other; Galderma: Advisory, Advisory Other; Millennium/Takeda: Research Funding, SAC/Advisory Other; Kyowa-Hakko-Kirin: Research Funding, SAC/Advisory Other; Oncosec: Advisory Other; Seattle Genetics: Advisory, Advisory Other, Research Funding; SHAPE: Consultancy, Research Funding. Off Label Use: Treatment of cutaneous T-cell lymphoma, also recently added to NCCN NHL practice guidelines in CTCL. Wood:Millennium: IDMC Other. Advani:Seattle Genetics: Research Funding. Horwitz:Millennium: Consultancy, Research Funding; Infinity: Research Funding; Kiowa-Kirin: Research Funding; Seattle Genetics: Consultancy, Research Funding; Spectrum: Research Funding; Amgen: Consultancy; Bristol-Myers Squibb: Consultancy; Celgene: Consultancy, Research Funding.

Evaluation of Health Related Questionnaire Among Mycosis Fungoides and Lymphomatoid Papulosis

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5603-5603 ◽  
Author(s):  
Rakhshandra Talpur ◽  
Iris Wieser ◽  
Casey Wang ◽  
Lyons Genevieve ◽  
Madeleine Duvic
Keyword(s):  
Quality Of Life ◽  
Board Of Directors ◽  
Mycosis Fungoides ◽  
Research Funding ◽  
Brentuximab Vedotin ◽  
Function Score ◽  
Advisory Committees ◽  
Significant Difference ◽  
And Function

Abstract INTRODUCTION AND OBJECTIVES: Mycosis Fungoides (MF) andlymphomatoid papulosis (LyP) are relatively rare and itchy skin disorders. The cosmetic disfigurement and severe pruritus dramatically affects the patient's quality of life. The focus is to examine the validity and reliability of the skindex-29, M.D. Anderson symptom inventory (MDASI) and itch-related quality of life (IQOL) questionnaire in 62 patients in a phase II trial of Brentuximab Vedotin. MATERIALS AND METHODS: Patients completed survey questionnaires related to symptoms and quality-of-life several times over the course of Brentuximab Vedotin. We compared patients' baseline scores to their end-of-study (EOS) scores. Patients were grouped by diagnosis into Mycosis Fungoides and Lymphomatoid papulosis group. Questionnaires included skindex-29, focusing on the skin conditions the patient was bothered the most. (MDASI) for patients with cancer and following the symptoms of cancer and the itchy quality of life (I-QoL) questionnaire was developed to measure the symptoms associated with cancer therapeutic agents and their effect on daily activities. Scoring for the Skindex-29, M. D. Anderson Symptom Inventory (MDASI) and the Quality of Life (QOL) survey were done according to the questionnaire specific scoring guide. Responses were compared between 2 groups using the Wilcoxon rank-sum test. RESULTS Questionnaires from 62 patients (23 LyP and 39 MF) were studied at baseline and end of study. Patients were 33 males and 29 females with median age of 60 years (range: 27-86 years). The median overall survival (OS) was significant P = 0.041, when comparing patients with MF to LyP. The median survival time for patients from time of diagnosis with MF was 14.66 years and LyP was not reached. There was no significant difference in progression free survival (PFS) between MF and LyP. The median number of Brentuximab Vedotin cycles was 7 (1-19). Skindex-29 scales, showed change in emotion scale and function scale from baseline to EOS, both groups had a decrease, patients with LyP had a larger decrease in emotion score (P = 0.069) and function score (P =0.096) over the course of the study. There was no difference in the symptom scale from baseline to EOS. The patients with LyP had a larger decrease in function score from baseline to EOS. When comparing patients with MF to those with LyP for MDASI, there is no evidence of a difference, from baseline to EOS, in either symptom severity or symptom interference in daily life. In the IQOL when comparing the LyP patients' QOL responses from baseline to EOS, did not show significant difference. Table 1. Change in Skindex-29 scales, by group Skindex Scale MF LYP p-value Change from baseline to end-of-study: N Median Min Max N Median Min Max Emotion 35 -10 -65 35 20 -22.50 -61.94 12.5 0.0698 Symptoms 35 -7.14 -46.43 42.86 20 -10.71 -53.57 28.57 0.4782 Function 35 -2.08 -50.38 27.08 20 -16.29 -44.70 14.58 0.0962 Table 2. Change in MDASI scales, by Diagnosis MDASI Scale Item MF LYP p-value Change from baseline to end-of-study: N Median Mean Std. Dev Range N Median Mean Std. Dev Range Severity 35 0.23 0.18 1.96 (-5.85, 3.15) 21 0.38 0.46 1.61 (-1.69, 5.0) 0.9595 Interference 35 0.17 0.06 3.07 (-9.17, 5.17) 19 0.0 0.11 1.59 (-3.0, 4.67) 0.6764 CONCLUSIONS A significant improvement in emotions and functional part of skindex-29 was observed when comparing patients with MF to patients with LyP. While both groups had a decrease, the patients with LyP had a larger decrease in emotion and function score over the course of the study. Disclosures Duvic: Celgene: Membership on an entity's Board of Directors or advisory committees; Rhizen Pharma: Research Funding; Allos (spectrum): Research Funding; Therakos: Research Funding, Speakers Bureau; Soligenics: Research Funding; Huya Bioscience Int'l: Consultancy; Spatz Foundation: Research Funding; MiRagen Therapeutics: Consultancy; Eisai: Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Millennium Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research Funding; Oncoceutics: Research Funding; Array Biopharma: Consultancy; Cell Medica Ltd: Consultancy; Tetralogics SHAPE: Research Funding; Innate Pharma: Research Funding; Kyowa Hakko Kirin, Co: Membership on an entity's Board of Directors or advisory committees, Research Funding.

scholarly journals Oral mycosis fungoides with CD30+ large cell transformation successfully treated with brentuximab vedotin

2019 ◽  
Vol 5 (2) ◽  
pp. 180-183
Author(s):  
Clare A. Goggins ◽  
M. Timothy Gocke ◽  
Sekwon Jang ◽  
Jennifer A. DeSimone
Keyword(s):  
Mycosis Fungoides ◽  
Cell Transformation ◽  
Large Cell ◽  
Brentuximab Vedotin ◽  
Large Cell Transformation
Sign in / Sign up

Export Citation Format

Share Document